Real-world Results of Ocrelizumab in the Treatment of Multiple Sclerosis: A Gulf Region Single-center Experience

INTRODUCTION: This study aimed to describe the real-world effectiveness and tolerability of ocrelizumab treatment at MS Clinic, Tawam Hospital.
METHODS: This retrospective, observational, single-center study analyzed the medical records of patients with multiple sclerosis (MS) receiving the standard dose of ocrelizumab.
RESULTS: After starting ocrelizumab, 3 of the 19 patients included in the study experienced disease progression, 3 showed disability improvement,
and the remaining 13 had stable status. None of the 15 patients with relapsing-remitting MS experienced a relapse. The average expanded disability status scale of all patients dropped from 2.32 to 2.22, when switched to ocrelizumab. After the follow-up period, 16 (84.21%) patients did not have any magnetic resonance imaging activity.
DISCUSSION AND CONCLUSION: As an MS treatment, ocrelizumab is associated with a favorable response in terms of both efficacy and safety in clinical practice
settings. The efficacy and safety demonstrated must be further evaluated to provide real-world evidence for the use of ocrelizumab.